Previous Page  29 / 50 Next Page
Information
Show Menu
Previous Page 29 / 50 Next Page
Page Background

Notes:

Page 47

Gastro 2016

August 11-12, 2016

Volume 6, Issue 4(Suppl)

J Gastrointest Dig Syst 2016

ISSN:2161-069X JGDS, an open access journal

conferenceseries

.com

August 11-12, 2016 Birmingham, UK

6

th

Global Gastroenterologists Meeting

EslamAhmed Habba, J Gastrointest Dig Syst 2016, 6:4(Suppl)

http://dx.doi.org/10.4172/2161-069X.C1.034

Hepatoma recurrence after Radiofrequency Ablation (RFA) in Egyptian patients with HCV

Eslam Ahmed Habba

Tanta University, Egypt

R

adiofrequency ablation (RFA) is the treatment of choice for patients with an early-stage Hepatocellular Carcinoma (HCC)

who are not candidates for surgical management; however, it is associated with a recurrence rate as high as 15–30% after

one year. The aim of this study was to analyze the risk factors for HCC recurrence in Egyptian patients after RFA. This study

was conducted on 45 HCC patients presented at two large referral centers for management of HCC in Egypt. Only patients with

an early-stage HCC, eligible for RFA, were included in the analysis and were followed up for a period of one year and grouped

into 2 groups: Group I which included patients with HCC recurrence during follow-up (n=30) and Group II with patients who

did not show any recurrence during follow-up (n=15). The risk factors associated with recurrence included smoking (70% in

Group I vs. 40% in Group II), hepatomegaly (50% in Group I vs. 40% in Group II), splenomegaly (90% in Group I vs. 53.3% in

Group II), heterogeneous liver (30% in Group I vs. 6.66% in Group II), bilobar involvement (20% in Group I vs. 6.66% in Group

II), and tumors in contact with hepatic capsule (20% in Group I vs. 6.66% in Group II). Hepatomegaly, liver heterogeneity,

and splenomegaly (a sign of portal hypertension) together with the tumor factors such as large size, bilobar involvement, and

proximity to liver capsule were the factors that showed a significant association with tumor recurrence in this study.

Biography

EslamAhmed Habba is an Assistant Lecturer of Hepatology, Gastroenterology and Infectious Diseases at Tropical Medicine department, Faculty of Medicine, Tanta

University Hospitals, Egypt. He is an active member of European Association for the Study of Liver (EASL). Also, he is a member of American Association for Study

of Liver Diseases (AASLD) and a member of Liver Tumors Committee at new Tanta University Teaching Hospital. He has some published papers in the field of

Hepatology and Infections. Recently, he had a published book about Hepatocellular Carcinoma.

eah2007@yahoo.com